Phase 3Completed
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
- Sponsor
- Esperion Therapeutics, Inc. (Industry)
- Enrolment
- 13,970 enrolled
- Conditions
- Cardiovascular Diseases; Statin Adverse Reaction
- Interventions
- Bempedoic acid 180 mg tablet; Matching placebo tablet
- Ages
- adults, older adults
- Registry
- NCT02993406
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
Primary outcomes
- Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)
History
Results first posted
Last registry update
Primary completion
Started
Registered